orr for all evaluable patients

- Differentiated Mechanism of Action of a Chimeric Degrader as Compared to Fulvestrant and Novel SERDs - - Treatment with AC699 Monotherapy Resulted in 21% ORR for All Evaluable Patients, and 50% for Those Who Had an ESR1 Mutation - - Favorable Safety and Tolerability Profile at All Doses with No DLTs or ≥ Grade 3 Adverse Events Related to AC699 - ...